Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Hemophilia A is a rare bleeding disorder caused by a genetically encoded factor VIII mutation that affects blood clotting. sick...
Read Full NewsPeople with worsening cardiovascular-kidney-metabolic syndrome may face an increased risk for developing age-related macular degeneration.
Use of topiramate is linked to a higher risk for glaucoma than valproate or lamotrigine, especially in women and patients with epilepsy, new research shows.
Using millions of NHS records, researchers mapped extensive links between childhood eczema and later inflammatory and eye diseases.
In patients with psoriasis, biologics may reduce ocular surface and corneal inflammation — especially dry eye, conjunctivitis, and keratitis — but they do not consistently alleviate retinal disease.
The second annual NCDB report reveals a major shift toward preoperative systemic therapy in solid tumors, offering new opportunities for de-escalation, although careful patient selection is needed.
Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis.
Metabolic syndrome, rather than BMI or waist circumference, is linked to an increased likelihood of glaucoma and may better identify adults who could benefit from closer eye screening.
1.
Durvalumab Wins FDA Approval in Limited-Stage SCLC
2.
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
3.
MRI can save rectal cancer patients from surgery, study suggests
4.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
5.
An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.
1.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
2.
Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results
3.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
4.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
5.
Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge